Next Article in Journal
Synthesis and Evaluation of a Chitosan-Based Cationic Hydrogel with Strong Antifungal and Antibiofilm Activities Against Clinical Isolates of Candida auris
Previous Article in Journal
Clove (Syzygium aromaticum) Pods: Revealing Their Antioxidant Potential via GC-MS Analysis and Computational Insights
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 18
Issue 4
10.3390/ph18040505
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Correction to Pharmaceuticals 2022, 15(8), 916.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Kammoun et al. Etodolac Fortified Sodium Deoxycholate Stabilized Zein Nanoplatforms for Augmented Repositioning Profile in Human Hepatocellular Carcinoma: Assessment of Bioaccessibility, Anti-Proliferation, Pro-Apoptosis and Oxidant Potentials in HepG2 Cells. Pharmaceuticals 2022, 15, 916

by
Ahmed K. Kammoun
1,
Maha A. Hegazy
2,
Alaa Khedr
1,
Zuhier Ahmed Awan
3,
Maan T. Khayat
1 and
Majid Mohammad Al-Sawahli
4,*
1
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University, P.O. Box 80260, Jeddah 21589, Saudi Arabia
2
Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo 11562, Egypt
3
Department of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz University, P.O. Box 80260, Jeddah 21589, Saudi Arabia
4
Department of Pharmaceutics, College of Pharmacy, The Islamic University, Najaf 54001, Iraq
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2025, 18(4), 505; https://doi.org/10.3390/ph18040505
Submission received: 11 March 2025 / Accepted: 24 March 2025 / Published: 31 March 2025
Browse Figure
Versions Notes

Text Correction (1)

There was an error in the original publication [1]. There was an error in 3.9. Annexin-V Assay, the flow cytometer was not identified. A correction has been made to 3. Materials and Methods, 3.9. Annexin-V Assay.
This assay was performed as described by [18,30] using the same cell culture plates, kit, reagents, and IC50 value for 24 h incubation. The apparatus used was Northern Lights 2000 spectral flow cytometer from Cytek Biosciences, USA, together with SpectroFloTM Software version 2.2.0.3.

Text Correction (2)

There was an error in the second paragraph of 2.7. Annexin-V Assay, our results were an argument for early and late apoptotic death and total cell death, which influence the pattern of ETD to induce apoptosis in HCC cells. A correction has been made to 2. Results and Discussion, 2.7. Annexin-V Assay.
The developed nanoplatforms—ETD-SDZN NSs—obtained the most potent pattern in augmenting the pre-G phase, which concluded apoptotic cell death confirmed by the annexin-V staining assay. Our results were an argument for late apoptotic death.

Error in Figure 8

In the original publication, there was a mistake in Figure 8 as published. The corrected Figure 8 appears below. This mistake may have originated from mislabeling of the annexin-V figures and subfigures in my digital archive.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Kammoun, A.K.; Hegazy, M.A.; Khedr, A.; Awan, Z.A.; Khayat, M.T.; Al-Sawahli, M.M. Etodolac Fortified Sodium Deoxycholate Stabilized Zein Nanoplatforms for Augmented Repositioning Profile in Human Hepatocellular Carcinoma: Assessment of Bioaccessibility, Anti-Proliferation, Pro-Apoptosis and Oxidant Potentials in HepG2 Cells. Pharmaceuticals 2022, 15, 916. [Google Scholar] [CrossRef] [PubMed]
Pharmaceuticals 18 00505 g008
Figure 8. Impact of ETD-SDZN NSs on annexin-V FITC positive staining HepG2 cells. (a) Control, (b) ETD, (c) SDZN NSs, (d) ETD-SDZN NSs, (e) Graphical presentation of early and late apoptotic, necrotic and total cell death.
Figure 8. Impact of ETD-SDZN NSs on annexin-V FITC positive staining HepG2 cells. (a) Control, (b) ETD, (c) SDZN NSs, (d) ETD-SDZN NSs, (e) Graphical presentation of early and late apoptotic, necrotic and total cell death.
Pharmaceuticals 18 00505 g008
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Kammoun, A.K.; Hegazy, M.A.; Khedr, A.; Awan, Z.A.; Khayat, M.T.; Al-Sawahli, M.M. Correction: Kammoun et al. Etodolac Fortified Sodium Deoxycholate Stabilized Zein Nanoplatforms for Augmented Repositioning Profile in Human Hepatocellular Carcinoma: Assessment of Bioaccessibility, Anti-Proliferation, Pro-Apoptosis and Oxidant Potentials in HepG2 Cells. Pharmaceuticals 2022, 15, 916. Pharmaceuticals 2025, 18, 505. https://doi.org/10.3390/ph18040505

AMA Style

Kammoun AK, Hegazy MA, Khedr A, Awan ZA, Khayat MT, Al-Sawahli MM. Correction: Kammoun et al. Etodolac Fortified Sodium Deoxycholate Stabilized Zein Nanoplatforms for Augmented Repositioning Profile in Human Hepatocellular Carcinoma: Assessment of Bioaccessibility, Anti-Proliferation, Pro-Apoptosis and Oxidant Potentials in HepG2 Cells. Pharmaceuticals 2022, 15, 916. Pharmaceuticals. 2025; 18(4):505. https://doi.org/10.3390/ph18040505

Chicago/Turabian Style

Kammoun, Ahmed K., Maha A. Hegazy, Alaa Khedr, Zuhier Ahmed Awan, Maan T. Khayat, and Majid Mohammad Al-Sawahli. 2025. "Correction: Kammoun et al. Etodolac Fortified Sodium Deoxycholate Stabilized Zein Nanoplatforms for Augmented Repositioning Profile in Human Hepatocellular Carcinoma: Assessment of Bioaccessibility, Anti-Proliferation, Pro-Apoptosis and Oxidant Potentials in HepG2 Cells. Pharmaceuticals 2022, 15, 916" Pharmaceuticals 18, no. 4: 505. https://doi.org/10.3390/ph18040505

APA Style

Kammoun, A. K., Hegazy, M. A., Khedr, A., Awan, Z. A., Khayat, M. T., & Al-Sawahli, M. M. (2025). Correction: Kammoun et al. Etodolac Fortified Sodium Deoxycholate Stabilized Zein Nanoplatforms for Augmented Repositioning Profile in Human Hepatocellular Carcinoma: Assessment of Bioaccessibility, Anti-Proliferation, Pro-Apoptosis and Oxidant Potentials in HepG2 Cells. Pharmaceuticals 2022, 15, 916. Pharmaceuticals, 18(4), 505. https://doi.org/10.3390/ph18040505

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop